Oral fluoropyrimidines in the treatment of colorectal cancer

European Journal of Cancer

Volumn 34, Issue 10, 1998, Pages 1509-1513

  Meropol, N J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

5 Fluorouracil; Capecitabine; Colorectal cancer; Ethynyluracil; Oral chemotherapy; S 1; Tegafur

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROPYRIMIDINE; FOLINIC ACID; OXONIC ACID; TEGAFUR; UFT; URACIL;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0032168166     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00226-3     Document Type: Article

References (51)

1. 1. Heidelberger C, Chaudhuari NK, Danenberg P, et al. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 1957, 179, 663-666.
2. 2. Meropol NJ, Creaven PJ, Petrelli NJ. Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Semin Oncol 1995, 22, 509-524.
3. 3. Piedbois R, Buyse M, Rustum YM, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 6, 896-903.
4. 4. Poon MA, O'Connell J, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 10, 1407-1418.
5. 5. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol 1993, 11, 1879-1887.
6. 6. Hrushesky WJM, Bjarnason GA. Circadian cancer therapy. J Clin Oncol 1993, 11, 1403-1417.
7. 7. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a southwest oncology group study. J Clin Oncol 1995, 13, 1303-1311.
8. 8. Blanke CD, Kasimis B, Schein P, Capizzi R, Kurman M. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997, 15, 915-920.
9. 9. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15, 110-115.
10. 10. Grem JL. Fluoropyrimidines. In Chabner BA, Longo DL eds. Cancer Chemotherapy and Biotherapy. Philadelphia, Lippincott-Raven. 1996, 149-211.
11. 11. Buroker T, Padilla F, Groppe C, et al. Phase II evaluation of ftorafur in previously untreated colorectal cancer. Cancer 1979, 44, 48-51.
12. 12. Friedman MA, Ignoffo RJ. A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treat Rev 1980, 7, 205-213.
13. 13. Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979, 70, 209-214.
14. 14. Kawaguchi Y, Nagayama S, Masuda H, Masuda H, Yasuda A. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats. Gann 1980, 71, 889-899.
15. 15. Fujii S, Ikenaka K, Masakazu F, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978, 69, 763-772.
16. 16. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988, 22, 333-338.
17. 17. Petreilli M, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989, 7, 1419-1426.
18. 18. Hansen RM, Ryan L, Anderson T, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996, 88, 668-674.
19. 19. Meropol NJ, Rustum YM, Petrelli NJ, et al. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 1996, 37, 581-586.
20. 20. Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994, 12, 2296-2300.
21. 21. Saltz LB, Leichman CG, Young CW, et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin: an active oral regimen for advanced colorectal cancer. Cancer 1995, 75, 782-785.
22. 22. Pazdur R, Covington WP, Brown NS, Lassere Y, Diaz-Canton E, Ho DH. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU). Proc Am Soc Clin Oncology 1996, 15 (abstract), 474.
23. 23. Pazdur R, Patt Y, Ajani J, et al. Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory, colorectal cancer patients. Proc Am Soc Clin Oncol 1997, 16 (abstract), 270a.
24. 24. Meropol NJ, Sonnichsen DS, Birkhofer MJ, Ferreira I, Noel D. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refactory colorectal cancer. Cancer Chemother Pharmacol (in press).
25. 25. Gonzalez-Baron M, Feliu J, de la Gandara I, et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995, 31, 2215-2219.
26. 26. Straw JA, Szapary D, Wynn MT. Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 1984, 44, 3114-3119.
27. 27. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331, 502-507.
28. 28. Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994, 12, 2239-2242.
29. 29. Davis ST, Joyner SS, Baccanari DP, Spector T. 5-ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem Pharmacol 1994, 48, 233-236.
30. 30. Porter DJT, Chestnut WG, Merrill BM, Spector T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem 1992, 267, 5236-5242.
31. 31. Spector T, Porter DJT, Nelson DJ, et al. 5-ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs Future 1994, 19, 656-671.
32. 32. Cao S, Rustum YM, Spector T. 5-ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994, 54, 1507-1510.
33. 33. Spector T, Cao S, Rustum YM, Harrington JA, Porter DJ. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 1995, 55, 1239-1241.
34. 34. Baker SD, Khor SP, Adjei AA, et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1994, 14, 3085-3096.
35. 35. Schilsky RL, Burris H, Ratain M, et al. Phase I clinical and pharmacologic study of 776C85 (776) plus 5-fluorouracil (FU) in patients with advanced cancer. Proc Am Soc Clin Oncol 1996, 15 (abstract), 485.
36. 36. Schilsky R, Bukowski R, Burris H, et al. A phase II study of a five day regimen of oral 5-fluorouracil (5-FU) plus GW776 (776C85) with or without leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997, 16 (abstract), 271.
37. 37. Baker SD, Diasio R, Lucas VS, et al. Phase I and pharmacologic study of oral 5-fluorouracil (5-FU) on a chronic 28-day schedule in combination with the dihydropyrimidine dehydrogenase (DPD) inactivator 776C85. Proc Am Soc Clin Oncol 1996, 15 (abstract), 486.
38. 38. Cao S, Shirasaka T, Rustum YM. Therapeutic selectivity of S-1, a new oral formulation of ftorafur (ft), 5-chloro-2,4-dihydroxypyridine (CDHP) and oxonic acid (oxo) in rats bearing advanced colorectal carcinoma. Proc Am Assoc Cancer Res 1995, 36 (abstract), 290.
39. 39. Rustum YM, Cao S, Shirasaka T, Taguchi T. A new 5-fluorouracil prodrug, S-1, orally bioavailable with high therapeutic index in model system active in phase II clinical trials. Proc Am Soc Clin Oncol 1997, 16 (abstract), 227.
40. 40. Cao S, Shirasak T, Rustum YM. Simultaneous inhibition of phosphoribosyl pyrophosphate transferase (PRPPT) and dihydropyrimidine dehydrogenase (DPD) enhances the therapeutic selectivity of Tegafur, a 5-fluorouracil prodrug, alone and in combination with cisplatin (CDDP). Proc Am Assoc Cancer Res 1996, 37 (abstract), 288.
41. 41. Taguchi T, Shirasaka T. New oral anticancer agent: S-1. Ann Oncol 1996, 7(Suppl 1) (abstract), 66.
42. 42. Peters GJ, van Groeningen CJ, Schomage, JH, et al. Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5-FU)-based antineoplastic agent. Proc Am Soc Clin Oncol 1997, 16, 227.
43. 43. Bajetta E, Colleoni M, DiBartolomeo M, et al. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol 1995, 13, 2613-2619.
44. 44. Cao S, Lu K, Ishitsuka H, Rustum YM. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol 1997, 16, 226.
45. 45. Ishikawa T, Utoh M, Sawada N, Sekiguchi F, Ishitsuka H. Zeloda (capecitabine): an orally available tumor-selective fluoropyrimidine carbamate. Proc Am Soc Clin Oncol 1997, 16 (abstract), 208.
46. 46. Ishikawa T, Sawada N, Sekiguchi F, Fukase Y, Ishitsuka H. Zeloda (capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Proc Am Soc Clin Oncol 1997, 16 (abstract), 226.
47. 47. Schuller J, Cassidy J, Reigner BG, et al. Tumor selectivity of xeloda in colorectal cancer patients. Proc Am Soc Clin Oncol 1997, 16 (abstract), 227.
48. 48. Meropol NJ, Budman DR, Creaven PJ, et al. A phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. Ann Oncol 1996, 7(Suppl. 1) (abstract), 87.
49. 49. Twelves C, Budman DR, Creaven PJ, et al. Pharmacokinetics (pk) and pharmacodynamics (pd) of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 1996, 15 (abstract), 476.
50. 50. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Ocol 1998, 16, 1795-1802.
51. 51. Findlay M, Van Cutsem E, Kocha W, et al. A randomized phase II study of xeloda (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997, 16 (abstract), 227.